• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Novo Nordisk - Articles and news items

2017 Pipelines: Drugs to watch

Blog, Z Homepage promo / 12 April 2017 / Alexandra Kibble, Senior Editor, Clarivate Analytics Cortellis

The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021…

New economic data finds Novo Nordisk’s insulin degludec most cost effective diabetic treatment

Industry news / 14 March 2017 / Niamh Marriott, Junior Editor

A new health economic analysis of two Phase 3b trials has demonstrated that Novo Nordisk’s Tresiba is a cost-effective option for diabetes…

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

NovoSeven resolved 96.5% of bleeds in haemophilia A or B sufferers

Industry news / 6 December 2016 / Niamh Louise Marriott, Digital Editor

NovoSeven, a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds demonstrating efficacy with haemophilia…

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

Post-meal hyperglycaemia has negative impact on diabetic quality of life

Industry news / 4 November 2016 / Niamh Louise Marriott, Digital Content Producer

New data from a study related to post-meal or postprandial glucose control, show that poor PPG control has a negative impact on diabetics quality of life…

Novo Nordisk’s semaglutide reduced major cardiovascular events in 1 in 4 type 2 diabetic adults

Industry news / 21 September 2016 / Niamh Louise Marriott, Digital Content Producer

Fewer serious adverse events were seen with semaglutide vs placebo; however, treatment discontinuation due to adverse events was more frequent…

Novo Nordisk’s insulin pen receives EU expanded use approval to treat more patients with type 2 diabetes

Industry news / 2 September 2016 / Niamh Louise Marriott, Digital Content Producer

The approval is based on data from the phase 3b clinical trial, which examined the efficacy and safety of liraglutide versus placebo as an add-on to existing diabetes medication, to improve glycaemic control…

NHS Scotland approves Novo Nordisk’s diabetes drug

Industry news / 9 August 2016 / Novo Nordisk

The drug was approved using evidence from three phase III studies in adults with type 1 diabetes mellitus and five phase III studies in adults with type 2 diabetes mellitus. The researchers discovered that insulin degludec was non-inferior to other long-acting insulin analogues, assessed by the mean change in glycosylated haemoglobin (HbA1c)…

Novo Nordisk presents new findings for Tresiba and semaglutide

Industry news / 13 June 2016 / Victoria White, Digital Content Producer

Novo Nordisk presented new findings from separate studies of Tresiba and semaglutide at the American Diabetes Association 76th Scientific Sessions…

Early response to Saxenda results in improvement in weight loss

Industry news / 3 June 2016 / Victoria White, Digital Content Producer

Three-year data show early response to Novo Nordisk’s Saxenda (liraglutide 3 mg) resulted in improvements in weight loss and cardiometabolic risk factors…

AbbVie tops the RepTrak ranking for most reputable pharma company in the UK

Industry news / 31 May 2016 / Victoria White, Digital Content Producer

Reputation Institute has announced that AbbVie, Sanofi and Novo Nordisk top the RepTrak ranking of the most reputable pharmaceutical companies in the UK…